Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $4.5600 (-5%) ($4.5400 - $4.5600) on Wed. Jan. 12, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.05% (three month average) | RSI | 38 | Latest Price | $4.5600(-5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.5% a day on average for past five trading days. | Weekly Trend | AUTL declines -5.8% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(66%) IBB(60%) IBUY(58%) ARKG(56%) ARKK(54%) | Factors Impacting AUTL price | AUTL will decline at least -2.525% in a week (0% probabilities). VIXM(-42%) VXX(-34%) TLT(-24%) SHY(-22%) TIP(-20%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.525% (StdDev 5.05%) | Hourly BBV | -1.5 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-6.88(-250.88%) | Resistance Level | $5.15 | 5 Day Moving Average | $4.7(-2.98%) | 10 Day Moving Average | $4.94(-7.69%) | 20 Day Moving Average | $5.15(-11.46%) | To recent high | -35.3% | To recent low | 0% | Market Cap | $238m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |